See the DrugPatentWatch profile for Basiliximab
What is basiliximab, and what does it do?
Basiliximab is an immunosuppressant medicine used to help prevent organ rejection, most commonly after kidney transplantation. It works by blocking the IL‑2 receptor on activated T cells, which reduces T‑cell–driven immune responses that can target the transplanted organ. [1]
When is basiliximab used in transplant patients?
It is used as part of immunosuppressive regimens in solid organ transplantation to lower the risk of acute rejection, especially in kidney transplant settings. [1]
How is it given (IV dosing schedules)?
Basiliximab is administered by intravenous infusion, typically given around the time of transplant as part of induction therapy (the exact schedule follows the prescribing information and local protocols). [1]
What side effects do people associate with basiliximab?
Commonly reported risks are related to infection and effects seen with immunosuppression. Specific adverse effects and their frequency depend on the overall regimen (for example, whether it is combined with other immunosuppressants) and patient factors. [1]
What drug interactions or precautions matter?
Because basiliximab changes immune activity, clinicians focus on infection risk and careful monitoring. Any additional immunosuppressive drugs taken alongside it can increase overall immunosuppression. [1]
How does basiliximab compare with other induction immunosuppressants?
Basiliximab is often described as a biologic that targets the IL‑2 receptor on T cells. Other induction options (such as different antibody agents) act through different immune pathways, which can affect speed/intensity of immunosuppression and the side-effect profile. [1]
Who makes basiliximab, and is it available as a biosimilar?
Basiliximab is a targeted biologic product; availability of brands and any biosimilar options depends on country and market authorization. [1]
Sources
- https://www.ema.europa.eu/en/medicines/human/EPAR/sim(u)lect